Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAE001 in metastatic castration-resistant prostate cancer (Phase 1/2)
CTR20190796Phase 2Terminated
- Sponsor
- Laekna
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CFG920 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Laekna. Started Apr 2019; status: terminated.
02
Drugs
CFG920
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20190796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190796.